A practical reference on freeze-dried powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-24 and is reviewed periodically as new material appears.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 0.9 kDa | Depends on exact fragment sequence and counterion |
| Amino acid sequence | LKKTETQ (commonly cited) | Short actin-binding motif from thymosin beta-4 |
| Common salt form | Acetate salt | Trifluoroacetate also reported in research material |
| Reconstitution solvent | Sterile water or buffer | Gentle mixing; avoid vigorous agitation |
| Solution storage | -20 °C or lower | Aliquot to avoid repeated freeze-thaw cycles |
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Margot Kidder at IMDb Margot Kidder at the Internet Off-Broadway Database (archived) Article at thecanadianencyclopedia.ca Article: From paranoid delusions to orthomolecular medicine Archived May 14, 2011, at the Wayback Machine Canadian Film Encyclopedia The Best Damn Fiddler from Calabogie to Kaladar Brodesser-Akner, Taffy. "Margot Kidder," New York Times, December 27, 2018.
=== Toxicology data === In the 1990s, fialuridine (FIAU) was investigated in clinical trials. The first trial was a 10-day trial in which 43 patients, who were infected with HIV and hepatitis B, demonstrated effective antiviral activity. A subsequent second dose-ranging study was done on 24 patients with hepatitis B over a period of four weeks. The second trial showed significant viral suppression at intermediate doses. However, patients later relapsed, meaning that the viral infection had returned. A longer, 6-month NIH-sponsored, third trial was planned to be conducted, but severe toxicity emerged at patients who had participated in the second trial. Many severe and fatal adverse effects were reported, including lactic acidosis, acute liver failure, peripheral neuropathy, multiple organ failure, and mitochondrial toxicity. A 60-year-old patient died from liver failure and lactic acidosis four months after the second trial. During the third trial, many patients experienced unpleasant side effects such as nausea and vomiting to such an extent that the researchers decided to end the trial. A theory put forward by Dr. Yung-Chi Chang of Yale University in 1991, which hypothesize that FIAU damaged the mitochondrial DNA, thereby giving rise to delayed toxicity. Urgent attempts were subsequently made to counteract the loss of mitochondria. However, by July 16, three patients had died, of whom two had already received a liver transplant and one was waiting for one. By August 1993, two more patients reported to be gravely ill and two other patients had also died.
Albert Pinhasov (Hebrew: אלברט פנחסוב; born 9 February 1972) is the Rector of Ariel University. He is a researcher in the fields of Molecular Psychiatry and Psychopharmacology.He also served as Vice President and Dean for Research & Development and the Head of the Department of Molecular Biology at Ariel University. Albert Pinhasov was born on 9 February 1972 in the city of Namangan, Uzbekistan. From 1990 to 1994, he studied at the Gorky Academy of Medicine, in the city of Nizhny Novgorod, Russia. In 1994, he immigrated to Israel where he continued his education at Tel Aviv University. He was awarded a Master of Science degree (MSc) in 1998 and a PhD in the field of Molecular Biology and Clinical Biochemistry under the mentorship of Illana Gozes in 2002 from Tel Aviv University.
The function of intrinsic termination is to signal for the dissociation of the ternary elongation complex (TEC), which ends transcription and releases RNA polymerase and its associated cofactors as well as the new RNA transcript. Intrinsic termination occurs independently of the protein Rho, in contrast to Rho-dependent termination, where the Rho protein must act on the RNA polymerase in order for it to dissociate from the transcription complex. Here, there is no extra protein and the transcript forms its own loop structure. Intrinsic termination thus regulates the level of transcription as well, determining how many polymerases can transcribe a gene over a given period of time, and can help prevent interactions with neighboring chromosomes.
Sources: en.wikipedia.org
Detection of substituted phenethylamines, which include compounds such as 2C-B, MDMA, and other designer drugs, involves various analytical methods aimed at identifying these psychoactive substances. These compounds are structurally similar to amphetamines, making their detection challenging due to potential cross-reactivity in standard drug tests. Techniques like gas chromatography-mass spectrometry (GC-MS), liquid chromatography-mass spectrometry (LC-MS), and immunoassay screenings are commonly employed for accurate identification. Advanced methods like high-performance liquid chromatography (HPLC) allow for precise separation and quantification of these substances even at low concentrations. Given the rising use of these drugs in recreational settings, developing sensitive and specific detection techniques remains crucial in forensic toxicology and clinical diagnostics.
the stored elastic strain energy which is released as a crack grows. This is the thermodynamic driving force for fracture. the dissipated energy which includes plastic dissipation and the surface energy (and any other dissipative forces that may be at work). The dissipated energy provides the thermodynamic resistance to fracture. Then the total energy is:
ALS Alzheimer's disease, Bipolar disorder, schizophrenia, aging and senescence, anxiety disorders Cancer Cardiovascular disease Diabetes Huntington's disease Long Covid ME/CFS Parkinson's disease Sarcopenia The body, and each mutation, is modulated by other genome variants; the mutation that in one individual may cause liver disease might in another person cause a brain disorder. The severity of the specific defect may also be great or small. Some defects include exercise intolerance. Defects often affect the operation of the mitochondria and multiple tissues more severely, leading to multi-system diseases. It has also been reported that drug tolerant cancer cells have an increased number and size of mitochondria, which suggested an increase in mitochondrial biogenesis. A recent study in Nature Nanotechnology has reported that cancer cells can hijack the mitochondria from immune cells via physical tunneling nanotubes. As a rule, mitochondrial diseases are worse when the defective mitochondria are present in the muscles, cerebrum, or nerves, because these cells use more energy than most other cells in the body. Although mitochondrial diseases vary greatly in presentation from person to person, several major clinical categories of these conditions have been defined, based on the most common phenotypic features, symptoms, and signs associated with the particular mutations that tend to cause them. An outstanding question and area of research is whether ATP depletion or reactive oxygen species are in fact responsible for the observed phenotypic consequences.
==== Officer of the Order of the British Empire (OBE) ==== Civil Division James Kepou. For services to the community and local Government Council. Henry Raisi Kila. For services to commerce and the community. Tembon Niki. For services to local government. Wilson Peni. For services to the community.
=== Initiatives === Santosh Lad was appointed state representative to oversee the rescue operation in the worst flooded area of Uttarakhand, accompanied by a team headed by Hemanth Nimbalkar, Kari Gowda, and Naveen Raj Singh. After over ten days of rescue operations, the team was able to rescue everyone except 14 people for whom an extensive search was carried out.
Sources: en.wikipedia.org
Zita of Bourbon-Parma (Zita Maria delle Grazie Adelgonda Micaela Raffaela Gabriella Giuseppina Antonia Luisa Agnese; 9 May 1892 – 14 March 1989) was the last Empress of Austria and Queen of Hungary, in addition to other titles. She ascended to these titles when her husband, Charles I, became the last monarch of Austria-Hungary. She was declared Servant of God by Pope Benedict XVI. Born as the seventeenth child of the dispossessed Robert I, Duke of Parma, by his second wife, Infanta Maria Antonia of Portugal, Zita married Archduke Charles of Austria in 1911. Charles became heir presumptive to Emperor Franz Joseph I in 1914 after the assassination of his uncle Archduke Franz Ferdinand of Austria, and acceded to the throne in 1916 after the elderly emperor's death. After the end of World War I in 1918, the Habsburgs were deposed and the former empire became home to the states of Austria, Hungary, and Czechoslovakia, while other parts were annexed to or joined the Kingdom of the Serbs, Croats and Slovenes, Italy, Romania, and a reconstituted independent Poland. Charles and Zita left for exile in Switzerland and, after the failure of attempts to restore royal rule in Hungary, were subsequently removed from that country by the Allies to Madeira, where Charles died in 1922. After her husband's death, Zita and her son Otto served as symbols of unity for the exiled dynasty. A devout Catholic, she raised a large family after being widowed at the age of 29; she never remarried.
Vitamin A is a fat-soluble vitamin that is an essential nutrient. The term "vitamin A" encompasses a group of chemically related organic compounds that includes retinol, retinyl esters, and several provitamin (precursor) carotenoids, most notably β-carotene (beta-carotene). Vitamin A has multiple functions: growth during embryo development, maintaining the immune system, and healthy vision. For aiding vision specifically, it combines with the protein opsin to form rhodopsin, the light-absorbing molecule necessary for both low-light (scotopic vision) and color vision. Vitamin A occurs as two principal forms in foods: 1) retinoids, found in animal-sourced foods, either as retinol or bound to a fatty acid to become a retinyl ester, and 2) the carotenoids α-carotene (alpha-carotene), β-carotene, γ-carotene (gamma-carotene), and the xanthophyll beta-cryptoxanthin (all of which contain β-ionone rings) that function as provitamin A in herbivore and omnivore animals which possess the enzymes that cleave and convert provitamin carotenoids to retinol. Some carnivore species lack this enzyme. The other carotenoids do not have retinoid activity. Dietary retinol is absorbed from the digestive tract via passive diffusion. Unlike retinol, β-carotene is taken up by enterocytes by the membrane transporter protein scavenger receptor B1 (SCARB1), which is upregulated in times of vitamin A deficiency (VAD). Retinol is stored in lipid droplets in the liver.
== External links == Major+Histocompatibility+Complex at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Molecular Individuality Archived 2013-01-29 at the Wayback Machine—German online book (2012) NetMHC 3.0 server—predicts binding of peptides to a number of different MHC (HLA) alleles T-cell Group—Cardiff University The story of 2YF6: A Chicken MHC[link removed] RCSB Protein Data Bank: Molecule of the Month—Major Histocompatibility Complex dbMHC Home, NCBI's database of the Major Histocompatibility Complex
== Books == The Malay Dilemma (1970) ISBN 981-204-355-1 The Challenge (1986) ISBN 967-978-091-0 Regionalism, Globalism, and Spheres of Influence: ASEAN and the Challenge of Change into the 21st century (1989) ISBN 981-303-549-8 Mahathir, Great Malaysian Hero (1990) ISBN 983-9683-00-4 The Asia That Can Say No (1994) ISBN 433-405-217-7 The Pacific Rim in the 21st century (1995) The Challenges of Turmoil (1998) ISBN 967-978-652-8 The Way Forward (1998) ISBN 0-297-84229-3 A New Deal for Asia (1999) Islam & The Muslim Ummah (2001) ISBN 967-978-738-9 Globalisation and the New Realities (2002) Reflections on Asia (2002) ISBN 967-978-813-X The Malaysian Currency Crisis: How and why it Happened (2003) ISBN 967-978-756-7 Mahathir: 22 Years, 22 Voices (2003) Dr Mahathir Mohamad - Father of Sports Development (2003) Achieving True Globalisation (2004) ISBN 967-978-904-7 Islam, Knowledge, and Other Affairs (2006) ISBN 983-3698-03-4 Principles of Public Administration: An Introduction (2007) ISBN 978-983-195-253-5 Chedet.com Blog Merentasi Halangan (Bilingual) (2008) ISBN 967-969-589-1 A Doctor in the House: The Memoirs of Tun Dr Mahathir Mohamad (2011) ISBN 9789675997228 Doktor Umum: Memoir Tun Dr. Mahathir Mohamad (2012) ISBN 9789674150259 Blogging to Unblock (Book 2): A Citizen's Rights (2013) ISBN 9789679696288 Dr. M: Apa Habaq Orang Muda? (2016) ISBN 9789671367995 Capturing Hope: The Struggle Continues for a New Malaysia (2021) ISBN 9789672923183 A Conversation with Tun Dr Mahathir bin Mohamad: A Legacy of Leadership and Vision (2025) ISBN 9789670821436
During the mid-to-late 1950s Crick was very much intellectually engaged in sorting out the mystery of how proteins are synthesised. By 1958, Crick's thinking had matured and he could list in an orderly way all of the key features of the protein synthesis process:
Sources: en.wikipedia.org
Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.
Reversed-phase liquid chromatography separates components and reports purity from peak area. Mass spectrometry confirms the molecular mass expected for the sequence. Additional approaches such as peptide mapping or amino acid analysis provide independent confirmation.
Reported percentages depend on the analytical method, the detection wavelength, and whether salts and water are counted. A value above ninety-five percent by chromatography does not by itself establish a correct sequence. Different suppliers also calculate purity against different reference standards.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.